BioKier, Inc.

BioKier, Inc. is a biopharmaceutical company focused on developing innovative oral products for managing lipid and glucose levels, specifically targeting patients with type 2 diabetes and insulin resistance. BioKier, Inc. is dedicated to the development of products aimed at enhancing metabolic control for diabetes management.

Founded by Roger Nolan, the company is headquartered in Chapel Hill, US. The firm has raised a total of USD 1. 70 mn across funding rounds, with the most recent being a VENTURE DEBT round of USD 0. 15 mn on July 30, 2014.

The company has been involved in 5 total deals to date, reflecting its active engagement in the private investment landscape. BioKier, Inc. specializes in the development of innovative oral products aimed at managing lipid and glucose levels in patients, particularly those with type 2 diabetes and insulin resistance. The company’s primary offerings replicate the metabolic effects of bariatric surgery, an established treatment known for its effectiveness in resolving diabetes and enhancing cardiometabolic health.

BioKier's flagship products include BKR-017 and BKR-013, utilizing colon-targeted nutrient delivery mechanisms to improve gut hormone secretion and regulation of glucose and lipids. These products are currently undergoing clinical trials and have shown promising results. BioKier primarily serves the North American and European markets, focusing on healthcare providers, diabetes management programs, and research institutions. BioKier's revenue model principally centers around partnerships and clinical trial collaborations within the healthcare and pharmaceutical sectors.

The company facilitates direct-to-consumer transactions through healthcare providers who prescribe its products for diabetes management, especially as they near commercialization. While specific pricing structures for their products remain undisclosed, BioKier’s offerings are positioned competitively in the diabetes management market. Additionally, the company has received funding through grants, including a USD 3. 0 mn Phase IIb Small Business Innovation Research Grant, enhancing its capacity for R&D and clinical studies.

BioKier, Inc. plans to leverage its recent funding from the VENTURE DEBT round to support the ongoing clinical trials of its flagship products, BKR-017 and BKR-013. The company is actively seeking to expand its market presence in North America and Europe, targeting additional healthcare providers and diabetes management programs by the end of 2024. These strategic initiatives will position BioKier for future growth and enhanced market penetration.